The aim of this study is to evaluate the effect of c1odronate on apoptosis of human systemic lupus erythematosus circulating mononuclear cells and to analyze possible correlations with changes in autoantibody production in vitro. Lympho-monocytes from 20 SLE patients were isolated and incubated with or without addition of IIJ.M clodronate for 72 hours. Apoptosis and release of genomic material was assessed by immunofluorescent detection ofcleaved caspase-3 and by Cell-Death-Detection ELISAPLUS kit (Roche). Anti-Nucleosome IgG and anti-dsDNA IgM and IgG autoantibody levels were determined in supernatants by commercially available ELISA kits. Clodronate induced apoptosis in monocytes as confirmed by cleaved caspase-3 immunostaining and by quantification of cleaved nucleosome in the supernatants (treated 0.22±0.05 O.D. vs untreated 0.09±O.04 O.D.; P<O.OOl). This finding was coupled with a significant increasing in supernatants of IgG anti-Nucleosome (treated 6.5±1.1 vs untreated 5.5±O.6IU/mL; p=O.OOl) and IgM (treated 3.0±1.3 vs 2.2±O.9 IU/mL; p=0.02) and IgG (treated 4.0±1.8 vs untreated 2.8±1.5 IU/mL; p=0.02) anti-dsDNA autoantibody levels. Our findings stressed the proapoptotic activity of clodronate, as well as its potential autoimmunity induction in SLE mononuclear circulating cells. Clinical studies could clarify the role of bisphosphonates on autoantibody production and worsening of disease activity.
Systemic lupus erythematous (SLE) is an autoimmune disease of unclear aetiology affecting multiple organs, characterized by the generation of an immune response to intact nuclear antigens, especially nucleosome, histones and doublestranded DNA (l). Apoptosis or programmed cell death, is a normal component of the development, differentiation and health ofmulticellular organisms, warranting an adequate cellular turnover and homeostasis. The elimination of apoptotic cells and cell bodies by phagocytes represents an evolutionarily conserved way to prevent exposure of surrounding tissue to potentially cytotoxic, immunogenic, or inflammatory cellular contents (2) . The increased apoptosis or impaired clearance ofapoptotic material has been the most investigated event in human SLE (3, 4, 5) , and several authors have reported defects in the apoptotic process, from the very beginning to the post-death phenomena, as crucial in the etiopathogenesis of SLE. Different environmental agents may induce apoptosis, primarily infections, hormones, UV radiation; hyperthermia, and different drugs (i.e. DNA damaging agents and anticancer drugs; sulfasalazine, clorpromazine, colchicine, ticlopidine, etc.) (6) (7) .
Clodronate is a non-aminated bisphosphonate and pharmacological and clinical studies have demonstrated its effectiveness in the treatment of postmenopausal osteoporosis and in all conditions of excessive bone resorption (i.e. Paget's disease, hypercalcaemia of malignancy, and osteolytic metastases). As a non-hydrolysable analogue of the adenosine triphosphate (ATP), clodronate induces apoptosis in mononuclear linage cells both in vitro and in vivo (8) . This is probably due to the inhibition of ATP-dependent cellular enzymes and/or the binding to transcription nuclear factors (9) (10) . Therefore, the aim of this study in human SLE peripheral blood mononuclear circulating cells (PBMCs) is to evaluate the effect of clodronate on apoptosis and changes in autoantibody levels in vitro.
MATERIALSAND METHODS

Subjects
Twenty SLE and 10 healthy Caucasian women, matched for age, were enrolled in this study. In Table  I clinical and laboratory findings of our studied groups are reported. Diagnosis of SLE was made according to classification criteria of the American College of Rheumatology (11) . Healthy women were enrolled from blood donors of our University. All subjects underwent a general physical examination and fasting blood collection. The study, performed according to the principles of the Declaration of Helsinki, was approved by the Ethical Committee of the University "Campus Bio-Medico" of Rome, Italy, and informed written consent was obtained from each subject.
Cell separation and culture
Peripheral blood was collected in EDTA-vacuum tubes. Full blood was diluted 1:I with phosphate buffered saline (PBS). 7 ml of diluted blood was added to 3 ml of Lymphoprep, and the vial was centrifuged for 10 min at 2500 rpm. Plasma was stored at -20°C until assayed.
Mononuclear cells were removed from the interface and washed twice with PBS. Following the final wash, the cells were suspended in complete culture medium (RPMI-1640 containing 10% fetal bovine serum, penicillin! streptomycin and L-glutamine), and 5 x 10 5 cells/ml were incubated at 37°C in a humidified 95% air and 5% CO 2 atmosphere, with or without clodronate (Gift from Roche Diagnostics GmbH, Mannheim, Germany). Cell vitality test was performed with Trypan Blue (4:1 dilution).
Apoptosis analysis Immunofluorescence for cleaved Caspase 3 determination
Cells were fixed in 2% formalin followed by a brief incubation with cold Methanol. Cells were then permeabilized with 0.2% Triton-x for 10 min and 2% BSA was added for 30 min to block non-specific binding sites. Samples were then incubated overnight with mouse monoclonal anti-Caspase-J activated primary antibody (AbCam) at the dilution of 1/500 at room temperature. After washing three times in PBS solution Alexa Fluor 488 conjugated secondary anti-mouse IgG was applied on the specimens and incubated for 1 h at room temperature (Molecular Probes). Slides underwent washing three times, then were mounted in fluorescence anti-fading mounting medium (Vectashield). In negative control experiments the incubation with primary antibodies were omitted.
Slides were viewed under confocal microscope (Nikon) by two independent observers and images were acquired using a Nikon Arkon software Ver. 1.2. Semiquantitative evaluation of the proapoptotic effect of Clodronate was performed using NIH-released ImageJ software as previously described (12) . Briefly, this software allows structures to be selected on the basis of pixel intensity values in a given color channel. The image was transformed into gray luminance values ranging from 0 (black) to 255 (white). The image analyzer software automatically evaluated positive labeling by using a threshold method, i.e. selecting both pixels whose intensity level was greater than a threshold value and object dimensions (background) to avoid analysis of fluorescence artefacts or cells fragments. Results were given as fluorescence intensity arbitrary units (AU) adjusting the values for the ratio of the selected threshold area to the total area. At least 10 randomly chosen fields at lOX magnification were evaluated independently with this method, and in order to avoid eventual biases the observers were blinded as to the belonging group of each sample.
Histone-complexed DNA fragments (nucleosomes) quantification
The quantitative detection of histone-complexed DNA fragments (mono-and oligonucleosomes) was performed using the Cell-Death-Detection ELISA PLUS kit (Roche). The assay uses a one-step sandwich immunoassay to detect nucleosomes with a relative quantification of apoptosis. Since the assay does not require prelabeling of cells, it can detect internucleosomal degradation ofgenomic DNA during apoptosis. According to the manufacture's instructions, a supernatant aliquot was transferred to a streptavidin-coated well of the microplate where nucleosomes were incubated with two monoclonal antibodies: antihistone (biotin-labeled) and anti-DNA (peroxidase-conjugated). Antibodynucleosome complexes were bound to the microplate by the streptavidin. Then, washing the immobilized antibodyhistone complexes three times, cell components that were not immunoreactive were removed. Finally, incubating sample with peroxidase substrate (ABTS) the amount of colored product (and thus, ofimmobilized antibodyhistone complexes) was determined spectrophotometrically and expressed as optical absorbance (OA).
Cellular populations assessment
Mononuclear cells were evaluated in untreated and treated cultures of 10 SLE patients using a previously described procedure with slight modifications. In brief, cultured cells were stained with the BD Multitest 6-color TBNK reagent (Becton Dickinson), which reacts with CD3, CD4, CD8, CDl9, CD45, CDl6/56, cell surface epitopes. Cells were incubated with 10 III of monoclonal antibodies for 15 minutes at room temperature. Appropriately matched isotype controls (mouse IgG1) at the same protein concentration as the relevant antibody were used in all analyses. Immediately after a wash the samples were measured by flow cytometry. Flow cytometric analysis was conducted using a FACScanto flow cytometer (Becton Dickinson) operated at 488 nm, which detects six fluorescences. Data acquisition and analysis were performed with the FACS DIVA software (Becton Dickinson). Forward and side scatter signals were collected using linear scales; mononuclear cells were gated according to these parameters and lineage-specific antibodies. Fluorescence signals were collected on a logarithmic scale.
Autoantibody evaluation
Antinuclear antibody (ANA) detection was performed through immunofluorescence assay (IFA) on commercial Hep-2 cells (ImmunoConcepts, Sacramento, CA, USA) in phosphate buffered saline (PBS), in SLE patients and control subjects. Two observers using positive and negative reference samples in each run evaluated the results. Anti-Nucleosome IgG antibodies were assessed in SLE sera and culture supernatants by commercially available immunenzymatic assay (ELISA) (ORGENTEC Diagnostika GmbH; Mainz, Germany -ORG 604M). Analogously, both IgG and IgM double-strand DNA autoantibodies were evaluated with ELISA kits (ORGENTEC Diagnostika GmbH; Mainz, Germany -ORG 528; The Binding Site -Birmingham, UK -FARRZYMETM High Avidity anti dsDNA Kit; respectively). All procedures were performed according to the manufacture's instructions.
Statistical analysis
Statistical analysis was performed using version 5.0 of Graphpad Instat (GraphPad Software, San Diego, California, USA). Data are presented as mean ± SD for quantitative variables and as numbers and percentages for categorical variables. t-Student test was used to compare continuous variables, and analysis of variance (ANOVA) with Bonferroni post-hoc test was performed when appropriate, while nominal variables were analysed by Chi-square. Only differences with p<0.05 were considered statistically significant.
RESULTS
We performed a preliminary "dose finding" study in PBMCs cultures from blood donors. They were incubated for 72 hours with increasing concentrations of clodronate (0.0 I, 0.1, 1, 10 J.1M) and the amount of histone-complexed DNA fragments (nucleosomes) in supernatant was quantified. We observed that in untreated cultures the amount of n'bcleosome was 0.07±0.02 0.0., while in supernatants ofcells treated with 0.1 and 1 J.1M clodronate it was 0.10±0.03 0.0. (p<0.05) and 0.12±0.03 0.0. (p<O.OI), respectively, while in cultures treated with 10 J.1M clodronate low levels of nucleosome (0.08±0.01 0.0.) were observed (Fig.1A) . Previous pharmacokinetic studies of clodronate in humans demonstrated a C max of 10 J.1M with a Ty, of about 2 hours (13). Most likely 10 J.1M continuously present for 72 h results in toxic effect. According to these findings we decided to carry out our study using I J.1M of clodronate. The Trypan Blue test demonstrated a significant low vitality in cultures treated with 1 J.1M clodronate compared to untreated (55.6±5.5 % vs 74.2±6.4 % -p<O.OOOI).
After incubation with 1 J.1M clodronate the fluorescence intensity of the cleaved caspase-3 immunostaining evaluated by semiquantitative analysis was significantly higher in SLE treated (Fig.1B) . Table II , the evaluation of cell subtypes, performed to assess which cells underwent apoptotic process, demonstrated a significant reduction only in the monocytes, while the other cell population percentages did not significantly change after treatment with clodronate. In the supernatants of treated SLE mononuclear cells, significantly higher levels of anti-Nucleosome IgG antibodies were observed compared to untreated cultures (treated 6.5±1.l vs untreated 5.5±0.6 IU/mL; p=O.OOl) (Fig.  1C) . Moreover, anti-dsDNA autoantibodies IgM and IgG were significantly higher in 1 !!M clodronate treated cultures compared to untreated (dsDNA-IgM treated 3.0±1.3 vs 2.2±0.9 IU/mL; p=0.02 -dsDNA-IgG treated 4.0± 1.8 vs untreated 2.8±1.5 IU/mL; p=0.02) (Fig. 1D) .
As shown in
DISCUSSION
Several studies have evaluated the effects of bisphosphonates in bone metabolism over the course ofdifferent primary and secondary diseases affecting the skeleton, such as steroid-induced osteoporosis (14) . Connective tissue disease has been a good study model, considering the high doses and the prolonged periods of steroid use in these diseases. Many studies have been carried out in patients affected by SLE, demonstrating the effectiveness of clodronate and other bisphosphonates in bone mineral density increase (15) (16) .
Although clodronate has had a wide clinical use for over 30 years, only in the last ten years the molecular mechanisms by which this molecule and that of successive generations (i.e. alendronate, risedronate, ibandronate and zoledronate) biologically affect bone metabolism have been clarified (17) . Only few studies have investigated the potential immunologic effect of this agent,. stimulated, above all, by the evidence of action on non-bone metabolism related signs of the disease, such as phlogosis, indices changes, pro-inflammatory cytokine variations, and neoplastic lesion dimensions (18) (19) .
Since the second half of the nineties, both in vitro and in vivo studies on animal models have demonstrated clodronate's ability to induce apoptosis in monocyte/macrophage lineage cells (9, 20) .
Our study is the first carried out on an in vitro model of human SLE. In our experimental model we observed the ability of clodronate to induce apoptosis also in human PBMCs, and only monocyte/ macrophages are involved in this phenomenon. This finding is obtained with comparable dosages to those observed after parenteral administration of the drug and has higher significance in SLE cells.
Denny et al. (21) performed an analogue study on mice, documenting an accelerated apoptosis in spleen macrophages after clodronate liposome i.v, administration, both in lupus-prone NZBxSWR and non-lupus-prone DBF 1 mice. After the second administration they observed increased levels of anti-nucleosome IgG in these animals, and after the third administration only in lupus-prone mice there were significantly higher levels of anti-dsDNA antibodies. Furthermore, these authors detected in their in vivo model a lethal accelerated glomerulonephritis onset in NZBxSWR clodronatetreated mice. In our study we observed significantly higher levels of anti-nucleosome and anti-dsDNA autoantibodies in supernatants of treated cultures compared to untreated.
Several studies indicate a deregulation in apoptotic process as pivotal element in SLE pathogenesis (22) . In vivo and in vitro data suggest a predisposition of SLE patients' mononuclear cells, as well as in lupusprone mice, to undergo apoptosis (23) (24) . Further findings are concordant in indicating an insufficient clearance of apoptotic material by scavenger cells, over the course of SLE (25) (26) .
The main characteristic ofprogrammed cell death is considered the maintaining of cell membrane and the fast elimination of apoptotic material, without inflammatory answer and/or immune system activation (27) (28) . On the other hand, recent studies have hypothesized that, under particular conditions, apoptotic cells could promote a pro-inflammatory activation of the immune system through the stimulation and release of chemokines and proapoptotic molecules from macrophages (29) or by the Caspase-1 mediated release of inflammatory cytokines from death cells (30) (31) .
Therefore apoptotic cells could have immunologic effects which seem to be mediated by different factors, such as the amount of apoptotic material, the antigen presenting cell engulfment, antigen processing and presentation and cytokine release in the microenvironment (32) ; all conditions that have been demonstrated to be dysfunctional in SLE (33) .
In accordance with Denny and coil. (22) , autoreactive lymphocytes exposed to a prominent amount of nuclear antigens, induced by monocytemacrophages apoptosis, could have a relevant role in disease pathogenesis and severity. For this reason the exposition to apoptosis inductors, such as clodronate, might have a detrimental immunologic effect, that in healthy subjects is only transitory and auto-limiting thanks to normal functioning immune surveillance system. In SLE this circumstance, especially if recurring, could represent a trigger for disease activity. Translation of our ex vivo findings in clinical practice requires further in vivo investigations on humans to understand the real pathological impact of clodronate on autoimmunity processes.
In conclusion, our data seem to confirm the apoptotic effect of clodronate in human monocyte/ macrophages at "physiological" concentrations and this finding appears more evident in SLE cells. Moreover, in SLE cultures this condition seems to be coupled with higher disease specific autoantibody levels. Clinical studies become essential to clarify the immunologic role of clodronate, and other bisphosphonates, in the tangled processes that lead to autoimmunity in humans. More information is needed on the potential function of these drugs in disease activity of SLE patients in order to define their real hazard in clinical practice use.
